bioAffinity Technologies, Inc. filed a Form 8-K on September 22, 2026, disclosing that the company issued a press release announcing the presentation of two posters on its CyPath® Lung diagnostic at the 2026 NAVREF Annual Conference, scheduled for September 27-30, 2026, in Arlington, Virginia.

Key Highlights

  • Conference presentations: bioAffinity Technologies is presenting two posters at the 2026 NAVREF Annual Conference, September 27-30, 2026, in Arlington, Virginia.
  • Product featured: The posters highlight CyPath® Lung, described in the filing as the company's noninvasive lung cancer diagnostic.
  • Research focus: The posters cover CyPath® Lung in clinical practice and ongoing research evaluating the technology in veteran and military populations.
  • Event date: The press release was issued and the report was dated September 22, 2026.
  • Emerging growth company: bioAffinity Technologies indicated it qualifies as an emerging growth company under applicable SEC rules.

bioAffinity Technologies Highlights CyPath Lung Research at NAVREF 2026

According to the filing, bioAffinity Technologies, Inc. (NASDAQ:BIAF), a Delaware corporation headquartered in San Antonio, Texas, reported under Item 8.01 (Other Events) that it issued a press release on September 22, 2026. The press release announced the company's participation at the 2026 NAVREF Annual Conference, a gathering running from September 27 through September 30, 2026, in Arlington, Virginia.

The filing states the company is presenting two posters at the conference. The posters are described as highlighting CyPath® Lung "in clinical practice and ongoing research evaluating the technology in veteran and military populations." The filing does not provide additional clinical data, study results, or poster abstracts within the 8-K body itself; the press release is attached as Exhibit 99.1 and incorporated by reference.

The registrant's common stock trades on the Nasdaq Capital Market under the symbol BIAF, and its warrants to purchase common stock trade under the symbol BIAFW, also on the Nasdaq Capital Market. Common stock carries a par value of $0.007 per share, as stated on the filing's cover page. The 8-K was signed by Maria Zannes, President and Chief Executive Officer, on September 22, 2026.

What Was Disclosed

bioAffinity Technologies filed an 8-K disclosing a press release announcing two poster presentations on its CyPath® Lung diagnostic at the 2026 NAVREF Annual Conference, September 27-30, 2026, in Arlington, Virginia, with a focus on veteran and military population research.